Clinical research
Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself effective in yet another cancer indication.
RRP is a rare, potentially fatal orphan disease caused by the Human Papillomavirus (HPV), a common virus present in 80 percent of people worldwide
Two months after Pfizer and Astellas’ Xtandi won regulatory approval for a new indication in prostate cancer, the companies have released positive new data in another type of prostate cancer.
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
In 2014, Exelixis’ Cabometyx (cabozantinib) failed to show survival benefit as a monotherapy in prostate cancer.
Myovant to Seek Regulatory Approval of Uterine Fibroid Treatment Following Positive Late-Stage Trial
More than five million women suffer from symptoms of uterine fibroids, with more than half of them estimated to have received inadequate treatment. However, new data released by Myovant shows that concerns of inadequate treatment could soon change.
Late-stage data released from Regeneron highlights the importance of proactively providing Eylea to patients who have been diagnosed with moderately severe to severe NDPR.
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
PRESS RELEASES